Investment analysts at StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a research report issued on Saturday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Trading Up 1.3 %
Shares of TTNP opened at $5.60 on Friday. Titan Pharmaceuticals has a fifty-two week low of $4.24 and a fifty-two week high of $14.80. The stock has a fifty day moving average of $5.84 and a two-hundred day moving average of $6.54.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last released its earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) EPS for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Featured Stories
- Five stocks we like better than Titan Pharmaceuticals
- How Technical Indicators Can Help You Find Oversold Stocks
- Powering Your Portfolio: The Utility Sector’s Electrifying Surge
- Using the MarketBeat Dividend Tax Calculator
- Adobe Stock Builds Long-Term Value: Consider Buying on the Dip
- Why Invest in 5G? How to Invest in 5G Stocks
- Albemarle Jumps as Lithium Stock Buying Frenzy Takes Off
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
